We are live on ! Find out more
ACRV icon

Acrivon Therapeutics
ACRV

18 hedge funds and large institutions have $170M invested in Acrivon Therapeutics in 2022 Q4 according to their latest regulatory filings, with 18 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

71.64% more ownership

Funds ownership: 0% → 71.64% (+72%)

Holders
18
Holders Change
+18
Holders Change %
–
% of All Funds
0.29%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.03%
New
18
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
+$61.1M
2
PA
Perceptive Advisors
New York
+$38.2M
3
SCV
Sands Capital Ventures
Virginia
+$21M
4
Citadel Advisors
Citadel Advisors
Florida
+$20.7M
5
Marshall Wace
Marshall Wace
United Kingdom
+$15.5M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
RCM
1
RA Capital Management
Massachusetts
$55.4M +$61.1M +4,810,508 New
PA
2
Perceptive Advisors
New York
$34.7M +$38.2M +3,007,858 New
SCV
3
Sands Capital Ventures
Virginia
$19M +$21M +1,652,605 New
Citadel Advisors
4
Citadel Advisors
Florida
$18.2M +$20.7M +1,634,104 New
Marshall Wace
5
Marshall Wace
United Kingdom
$14.1M +$15.5M +1,223,252 New
Wellington Management Group
6
Wellington Management Group
Massachusetts
$9.99M +$11.4M +900,149 New
Federated Hermes
7
Federated Hermes
Pennsylvania
$9.48M +$10.5M +823,300 New
NMC
8
NEA Management Company
Maryland
$4.44M +$6.11M +481,677 New
HM
9
HealthCor Management
New York
$3.27M +$3.61M +284,201 New
Bank of Montreal
10
Bank of Montreal
Ontario, Canada
$545K +$539K +42,444 New
Goldman Sachs
11
Goldman Sachs
New York
$447K +$493K +38,800 New
Two Sigma Investments
12
Two Sigma Investments
New York
$248K +$273K +21,534 New
Millennium Management
13
Millennium Management
New York
$226K +$249K +19,639 New
DCM
14
DAFNA Capital Management
California
$180K +$199K +15,648 New
UBS Group
15
UBS Group
Switzerland
$54.7K +$60.3K +4,748 New
Barclays
16
Barclays
United Kingdom
$47.7K +$52.6K +4,142 New
Morgan Stanley
17
Morgan Stanley
New York
$10K +$11K +869 New
TRCT
18
Tower Research Capital (TRC)
New York
$2K +$2.02K +159 New

ACRV Hedge Fund Activity: Q4 2022 in Review

18 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Acrivon Therapeutics (ACRV) for Q4 2022, worth a combined $170M.

Buyers outnumbered sellers: 18 funds opened new ACRV positions and 0 closed out — a net gain of 18 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was RA Capital Management, opening a new position worth an estimated $61.1M.

  • 18 institutional investors held Acrivon Therapeutics (ACRV) as of Q4 2022, up from 0 in Q3 2022.
  • Funds reported $170M of Acrivon Therapeutics stock for Q4 2022.
  • 18 funds opened new Acrivon Therapeutics positions in Q4 2022 and 0 closed out, a net change of +18 holders.
  • The largest Acrivon Therapeutics buyer in Q4 2022 was RA Capital Management, an estimated $61.1M added.

Based on aggregated 13F filings for Q4 2022.